Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-649-2
CAS number: 123-76-2
300 mg/kg < LD50 (rat, oral) < 2000 mg/kg
LD50 (rat, dermal) > 2000 mg/kg
Acute oral toxicity
The acute toxicity of the test item was
investigated following a single oral administration to the Sprague
Dawley rat followed by a 14-day observation period. A first group of 3
female animals was initially dosed at 2000 mg/kg body weight. Mortality
occurred in all animals on Day 2. Hunched posture, piloerection and
decreased activity were observed on the day of dosing. A second group of
3 female animals was then dosed at lower dose level of 300 mg/kg. No
death occurred and no signs of toxicity were seen. A third group of 3
female animals was then dosed at the same dose level (300 mg/kg). No
death occurred and no signs of toxicity were seen. No abnormalities were
observed at necropsy examination in the early decedent animals and in
those sacrificed at the end of the observation period. These results
indicate that the test item induced effects of toxicological relevance
(mortality) in the rat following oral administration of a single dose at
2000 mg/kg. No mortality nor signs of toxicity were observed following
dosing at 300 mg/kg.
300 mg/kg < LD50 (rat, oral) < 2000
Acute inhalation toxicity
Not evaluated considering that the vapour
pressure of the substance suggests that the inhalation exposure is
unlikely to occur.
Acute dermal toxicity
The acute toxicity of the test material
was investigated following dermal administration of a single dose to the
rat, according to the OECD Guideline 402. A single dose of 2000 mg/kg
was administered to a group of 5 male and 5 female animals for 24 hours,
under semi-occlusive dressing. Animals were observed for mortality and
clinical signs and were weighed on the day of allocation, on the day of
dosing and on days 8 and 15. After 14 days, all animals were killed and
subjected to necropsy examination. No mortality occurred and no signs of
toxicity were observed in male or female animals during the observation
period. The body weight changes observed during the study were within
the expected range for this species and age of animals. No significant
abnormalities were found at necropsy in the animals at termination of
the study. No abnormalities were observed at the treated site.
LD50 > 2000 mg/kg
According to the CLP Regulation (EC)
No.1272/2008 Annex I: 184.108.40.206.: "Substances can be allocated to one of
four hazard categories based on acute toxicity by the oral, dermal or
inhalation route according to the numeric criteria shown in Table 3.1.1.
Acute toxicity values are expressed as (approximate) LD50 (oral, dermal)
or LC50 (inhalation) values or as acute toxicity estimates (ATE)."
The LD50 obtained in the acute dermal
toxicity study is above 2000 mg/kg bw and therefore no classification
applies. However, the LD50 obtained in the acute oral toxicity is
between 300 mg/kg bw and 2000 mg/kg bw and for this reason the substance
is classified in Category 4 (H302) according to the CLP
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Dette websted anvender cookies for at sikre dig den bedste brugeroplevelse.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again